Compositions for modulating the expression of aquaporins in diabetes and associated conditions
Patent Information
- Application Number
- PCT/US2024/026804
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-29
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-07
Smart Images

Figure US2024026804_07112024_PF_FP_ABST
Abstract
Description
COMPOSITIONS FOR MODULATING THE EXPRESSION OF AQUAPORINS IN DIABETES AND ASSOCIATED CONDITIONSFIELD OF INVENTION
[0001] The present invention in general relates to compositions comprising compounds of Formula I. More specifically, the invention relates io compositions comprising either Gingerenone A or Hirsutenone. Further specifically, the invention relates to a composition comprising either Gmgerenone A or Hirsutenone and methods thereof for use in modulating the expression of Aquaporins (AQP) in diabetes and for the management of diabetes and related complications thereof.BACKGROUND OF THE INVENTION
[0002] Water is the single largest constituent in the body weighing about 55-66% of the total body weight, distributed between the intracellular and extracellular components. The solutes in the water determine the osmotic pressure of the cell, which should be equal between intracellular and extracellular fluids. Thus, water should be transported easily between plasma membranes to maintain the osmotic pressure of the cells. Imbalance in the concentration of either the water or the solutes increases osmotic stress (hyperosmolarity and hypoosmolality) which is the primary cause for the developments of various diseases and disorders. Hyperosmolarity triggers cell shrinkage, oxidative stress, protein carbonylation, mitochondrial depolarization, DNA damage, and cell cycle arrest, thus rendering cells susceptible to apoptosis. Hypoosmotic stress can act as an inflammatory stimulus and is also associated with a number of disorders, including acetaminophen toxicity and brain edema (Brocker et al., The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012 Aug: 3(4): 345 364}. Thus, maintaining a stable water homeostasis is important to sustain a constant osmotic balance of the cells for maintaining general health and wellbeing.
[0003] Aquaporins (AQPs) are part of the family of the integral membrane proteins with a function to transport water, glycerol, ammonia, urea, H2O2, and other small molecules across the biological membranes. The expression levels of AQPs are essential for maintaining water homeostasis and they have a relevant role in the development of many diseases. Recent discoveries suggest, that AQPs play animportant role in the process of fat accumulation, regulation of oxidative stress, and two crucial aspects of insulin resistance, type-2 diabetes and obesity. Many AQPs viz AQP1, AQP4, AQP9, AQP17 have been implicated in diseases like diabetes, insulin resistance, neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, loss of vision, loss of skin barrier function, kidney diseases, xerostomia (dry mouth), and the edema that follows stroke or trauma to the brain or spinal cord etc (Salman el al., Recent breakthroughs and future directions in drugging aquaporins, Trends in Pharmacological Sciences, Volume 43, Issue 7, January 2022, Pages 30-42). Modulating the expression of these aquaporins has been touted as a possible drug target for the management of these diseases.
[0004] Several small molecules like 3,3'-( l,3-Phenylene)bis(2-propenoic acid), N- 1 ,3,4-Thiadiazol-2-yl-3-pyridinecarboxamide, were studied for modulating the activity and expression of AQPs (Salman et al., Recent breakthroughs and future directions in drugging aquaporins, Trends in Pharmacological Sciences, Volume 43, Issue 1, January 2022, Pages 30-42). Natural molecules like Bacopaside from Bacopa monneri has also been reported to modulate the expression of AQPs. However, most of the therapeutic interventions rely on managing the symptoms and currently no pharmacological interventions exist for any pathologies of aquaporin dysfunction. There exists an unmet clinical need for identifying new drug development frameworks and small molecules for conditions associated with imbalances in water and solute homeostasis and modulating aquaporin expression. The present invention solves the unmet need by disclosing a natural plant based compounds for modulating the expression of different aquaporins and in the management of aquaporin related diseases like neurodegenerative diseases, metabolic syndrome, cardiovascular diseases, cancer, inflammatory diseases, allergy, diabetes, insulin resistance, renal disorders, skin hydration, brain edema, immune system disorders, obesity', and liver steatosis, more specifically, for the management of diabetes and related conditions like insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy' and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma.
[0005] It is the principle object of the invention to disclose a composition comprising compounds of Formula I, wherein Ri is selected from the group consisting of methyl and H.Formula I
[0006] It is another object of the invention to disclose the use of a composition comprising compounds of Formula I and methods thereof for modulating the expression of aquaporins in a subject.
[0007] It is another object of the invention to disclose the use of a composition comprising compounds of Formula I and methods thereof for increasing and maintaining pancreatic {3-cell function in a subject.
[0008] It is yet another object of the invention to disclose the use of a composition comprising compounds of Formula I and methods thereof for management of diabetes and related complications in a subject.
[0009] The present invention solves the above-mentioned objects and provides further related advantages.SUMMARY OF THE INVENTION
[0010] In a most preferred embodiment, the invention discloses a composition comprising compounds of Formula IFormula IIn a related aspect of the invention, the compounds of Formula I wherein Ri is selected from the group consisting of methyl and H.
[0011] In another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I and methods thereof for modulating theexpression of aquaporins in a subject. In a related aspect of the invention, the compound is selected from the group consisting of Gingerenone A (STR#2) or Hirsutenone (STR#3).
[0012] In another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I and methods thereof for increasing the pancreatic P-cell function in a subject. In a related aspect of the invention, the compound is selected from the group consisting of Gingerenone A and Hirsutenone.
[0013] In yet another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I and methods thereof for therapeutic management of diabetes and related complications in a subject. In a related aspect of the invention, the compound is selected from the group consisting of Gingerenone A,and Hirsutenone.BRIEF DESCRIPTION OF DRAWINGS
[0014] Fig. 1 is a graphical representation showing the modulation of expression of aquaporin 7 in pancreatic cell supernatant of different groups of experimental animals fed with High fat diet and administered with Gingerenone, Hirsutenone and Metformin (control).
[0015] Fig. 2 is a graphical representation showing the modulation of expression of aquaporin 12 in pancreatic cell supernatant of different groups of experimental animals fed with High fat diet and administered with Gingerenone, Hirsutenone and Metformin (control).
[0016] Fig. 3 is a graphical representation showing the modulation of expression of NLRP-3 in pancreatic cell supernatant of different groups of experimental animals fed with High fat diet and administered with Gingerenone, Hirsutenone and Metformin (control).
[0017] Fig. 4 is a graphical representation showing the modulation of cystatin C levels in blood of different groups of experimental animals fed with High fat diet and administered w'ith Gingerenone, Hirsutenone and Metformin (control).DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTSSelected Definitions
[0018] All the terms used in this application carry ordinary meaning as known in the prior art unless otherwise specified. Few other specific definitions used in thisinvention are explained below, which applies throughout this specification. Claims provide broader definition unless and otherwise specified.
[0019] Furthermore, the terms "approximately,” "approximate,” "about," and similar terms generally refer to ranges that include the identified value within a mar gin of 20%, 10%, or preferably 5%, and any values there between.
[0020] As used herein, treatment or management of a condition refers to effectively ameliorating conditions disclosed in the invention. An effective dose refers to positive or modulatory effects of a condition in a subject covered under this invention.
[0021] In a most preferred embodiment, the invention discloses a composition comprising compounds of Formula IFormula I
[0022] In a related aspect of the invention, the compound is selected from the group consisting of Gingerenone A ( STR#2) and Hirsutenone. (STR#3).(STR#2) (STR#3)
[0023] In a preferred embodiment Gingerenone A and Hirsutenone are isolated from plant sources or chemically synthesised. In another embodiment of the invention, the plant source is preferably, but not limited to, Zingiber officinale, Alnus hirsuta, Alnus sibirica, Alnus glutinosa, Alnus formosana, Alnus japonica, Alnus nepalensis, Viscum cruciatum. In a related embodiment of the invention, wherein the composition further comprises carriers and excipients. In a related embodiment of the invention the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0024] In another most preferred embodiment, the invention discloses a method for modulating the expression of aquaporins in a subject with a disease condition comprising a) identifying the subject with the disease condition, b) administering an effective dose of a composition comprising compounds of Formula 1 to the said subject to bring about a change in the expression of aquaporins. In a related embodiment of the invention, the compound is selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3). In a related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQPO, AQPI, AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP11, AQP12, and combinations thereof. In a related embodiment of the invention, modulating tire expression of aquaporins improves water homeostasis in the subject. In another related embodiment of the invention, the disease condition is selected from the group consisting of neurodegenerative diseases, metabolic syndrome, cardiovascular diseases, cancer, inflammatory diseases, allergy, diabetes, insulin resistance, renal disorders, skin hydration, brain edema, immune system disorders, obesity, and liver steatosis. In a preferred embodiment of the invention, modulating the expression of aquaporins is useful for management of diseases and disorders selected from the group consisting of neurodegenerative diseases, diabetes, and insulin resistance. In another related embodiment, the effective dose of the compounds is in the range 2.5 - 40 mg / kg body weight of the subject. In another preferred embodiment, the subject is a mammal. In a related embodiment of the invention, the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0025] In another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I for use in modulating the expression of aquaporins in a subject with a disease condition. In a related embodiment of the invention, the compound is selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3). In a related embodiment of the invention, wherein the aquaporins is selected from the group consisting of AQPO, AQPI, AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP11, AQP12, and combinations thereof. In a related embodiment of the invention, modulating the expression of aquaporins improves water homeostasis in the subject. In another related embodiment of the invention, the disease condition is selected from the groupconsisting of neurodegenerative diseases, metabolic syndrome, cardiovascular diseases, cancer, inflammatory diseases, allergy, diabetes, insulin resistance, renal disorders, skin hydration, brain edema, immune system disorders, obesity, and liver steatosis. In a preferred embodiment of the invention, modulating the expression of aquaporins is useful for management of diseases and disorders selected from the group consisting of neurodegenerative diseases, diabetes, and insulin resistance. In another related embodiment, the effective dose of the compounds is in the range 2.5 - 40 mg / kg bodyweight of the subject. In another preferred embodiment, the subject is a mammal. In a related embodiment of the invention, the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables. .
[0026] In another most preferred embodiment, the invention discloses use of a composition comprising compounds of Formula I for modulating the expression of aquaporins in a subject with a disease condition, m a related embodiment of the invention, the compound is selected from the group consisting of Gingerenone A (STR&2) and Hirsutenone (STR#3). In a related embodiment of the invention, wherein the aquaporins is selected from the group consisting of AQPO, AQP1, AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP11, AQP12, and combinations thereof. In a related embodiment of the invention, modulating the expression of aquaporins improves water homeostasis in the subject. In another related embodiment of the invention, the disease condition is selected from the group consisting of neurodegenerative diseases, metabolic syndrome, cardiovascular diseases, cancer, inflammatory diseases, allergy, diabetes, insulin resistance, renal disorders, skin hydration, brain edema, immune system disorders, obesity, and liver steatosis. In a preferred embodiment of the invention, modulating the expression of aquaporins is useful for management of diseases and disorders selected from the group consisting of neurodegenerative diseases, diabetes, and insulin resistance. In another related embodiment of the invention, the effective dose of the compounds is in the range 2.5 - 40 mg / kg bodyweight of the subject. In another preferred embodiment, the subject is a mammal. In a related embodiment of the invention, the composition is formulated with pharmacally / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0027] In another most preferred embodiment, the invention discloses a method for increasing pancreatic P-cell function in a subject with a disease condition, comprising a) identifying the subject in need of improving pancreatic [3-cell function, b) administering an effective dose of a composition comprising compounds of Formula I to the subject to increase p-cell function by improving water homeostasis. In a related embodiment of the invention. the compound is selected from the group consisting of Gingerenone A (STR#2} and Hirsutenone (STR#.3). In a related aspect, the improvement of P-cell function and water homeostasis is brought about by modulating the expression of aquaporins (AQPs). In a related embodiment of the invention, wherein the aquaporins are selected from tire group consisting of AQPO. AQP1, AQP2, AQP3, AQP4, AQP5. AQP6, AQP8, AQP7, AQP9, AQP10, AQP1 1, AQP12, and combinations thereof. In another preferred embodiment, the aquaporins are selected from the group consisting of AQP7 and AQP12. In another preferred embodiment of the invention, altering the pancreatic p-cell function results in modulating the proliferation, adhesion and migration of pancreatic p-cells, decreases the levels of inflammatory cytokines and regularizes insulin secretion. In another related embodiment of the invention, the effective dose of the compounds is 2.5 - 40 mg / kg bodyweight of the subject. In a preferred embodiment of the invention, the effective dose is 10-20 mg / kg bodyweight of the subject. In another related embodiment of the invention, the diseases condition is selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In related embodiment of the invention the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0028] In another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I for use in increasing pancreatic p-cell function in a subject with a disease condition, wherein increase in p-cell function by the composition is brought about by improving water homeostasis. In a related embodiment of the invention, the compound is selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3). In a related aspect, theimprovement of p-cell function and water homeostasis is brought about by modulating the expression of aquaporins (AQP). In a related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQPO, AQP1, AQP2, AQP3. AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP1 1, AQP12, and combinations thereof. In another preferred embodiment of the invention, the aquaporins are selected from the group consisting of AQP7 and AQP 12. In another preferred embodiment of the invention, altering the pancreatic P-cell function results in modulating the proliferation, adhesion and migration of pancreatic P-cells, decreases the levels of inflammatory cytokines and regularizes insulin secretion. In another related embodiment of the invention, the effective dose of the compounds is 2.5 - 40 mg / kg bodyweight of the subject. In a preferred embodiment of the invention, the effective dose is 10-20 mg / kg bodyweight subject. In another related embodiment of the invention, the disease condition is selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In related embodiment of the invention, the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in tire form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0029] In another most preferred embodiment, the invention discloses use of a composition comprising compounds of Formula I in increasing pancreatic [3-cell function in a subject with a disease condition, wherein increase in p-cell function by the composition is brought about by improving water homeostasis. In a related embodiment of the invention, the compound is selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3). In a related aspect, the improvement of P-cell function and water homeostasis is brought about by modulating the expression of aquaporins (AQPs ). hr related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQPO, AQP1 , AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP11, AQP12, and combinations thereof. In another preferred embodiment of the invention, the aquaporins are selected from the group consisting of AQP7 and AQP 12. In another preferred embodiment of the invention, altering the pancreatic P-cell function results inmodulating the proliferation, adhesion and migration of pancreatic P-cells, decreases the levels of inflammatory'' cytokines and regularizes insulin secretion. In another related embodiment of the invention, the effective dose of the compounds is 2.5 - 40 mg / kg bodyweight of the subject. In a preferred embodiment of the invention, the effective dose is 10-20 mg / kg body weight subject. In another related embodiment of the invention, the diseases condition is selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In a related embodiment of the invention the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0030] In another most preferred embodiment, the invention discloses a method for therapeutic management of diabetes and related complications in a subject comprising a) identifying the subject with diabetes, b) administering an effective dose of a composition comprising compounds of Formula I to the subject. In related embodiment, the compound is selected from the group consisting of Oingereaone A (STR#2) and Hirsutenoue (S T.R#3). In a related aspect, management of diabetes is brought about by increasing the pancreatic [3-cell function, decreasing circulating levels of creatinine, and albumin, decreasing hyperlipidemia, decreasing blood cystatin C levels, and reducing expression of NLRP-3 inflammasomes. In a related aspect, the alteration of P-cell function is brought about by modulating the expression of aquaporins (AQP). In related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQP0, AQP1 , AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP10, AQP1 1 , AQP12, and combinations thereof. In another preferred embodiment, the aquaporins are selected from the group consisting of AQP7 and AQP12. In another related aspect, hyperlipidemia is reduced by decreasing the levels of triglycerides, total cholesterol, free fatty acids and phospholipids. In another related embodiment, the effective dose of the compounds is 2.5 - 40 mg / kg bodyweight of the subject. In a preferred embodiment of the invention, the effective dose is 10-20 mg / kg bodyweight of the subject. In another related embodiment, the related complications are selected from the group consisting of.insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In a related embodiment of the invention the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0031] In another most preferred embodiment, the invention discloses a composition comprising compounds of Formula I for use in the therapeutic management of diabetes and related complications in a subject. In a related embodiment of the invention, the compounds are selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3 ). In a related aspect, management of diabetes is brought about by increasing the pancreatic P-cell function, decreasing circulating levels of creatinine, and albumin, decreasing hyperlipidemia, decreasing blood cystatin C levels, and reducing expression of NLRP-3 inflammasomes. In a related aspect, the alteration of [3-cell function is brought about by modulating the expression of aquaporins (AQP). In a related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQPO, AQP1, AQP2, AQP3, AQP4, AQP5, AQP6, AQP8, AQP7, AQP9, AQP 10, AQP I L AQP 12. and combinations thereof. In another preferred embodiment of the invention, the aquaporins are selected from the group consisting of AQP7 and AQP12. In another related aspect, hyperlipidemia is reduced by decreasing the levels of triglycerides, total cholesterol, free fatty acids and phospholipids. In another related embodiment of the invention, the effective dose of the compounds is 2.5 - 40 mg / kg bodyweight of the subject. In a preferred embodiment of the invention, the effective dose is 10-20 mg / kg bodyweight of the subject. In another related embodiment of the invention, the related complications are selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In related embodiment of the invention, the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers,and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0032] In another most preferred embodiment, the invention discloses use of a composition comprising compounds of Formula I for the therapeutic management of diabetes and related complications in a subject. In related embodiment, the compounds are selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR#3). In a related aspect, management of diabetes is brought about by increasing the pancreatic p-cell function, decreasing circulating levels of creatinine, and albumin, decreasing hyperlipidemia, decreasing blood cystatin C levels, and reducing expression of NLRP-3 inflammasomes. In a related aspect, the alteration of p-cell function is brought about by modulating the expression of aquaporins (AQP). In a related embodiment of the invention, wherein the aquaporins are selected from the group consisting of AQPO, AQP1, AQP2, AQP3, AQP4, AQP5, AQP6, AQP8. AQP7, AQP9, AQP 10, AQP1 1, AQP 12, and combinations thereof. In another preferred embodiment of the invention, the aquaporins are selected from the group consisting of AQP7 and AQP 12. In another related aspect, hyperlipidemia is reduced by decreasing the levels of triglycerides, total cholesterol, free fatty acids and phospholipids. In another related embodiment of the invention, the effective dose of the compounds is 2.5 - 40 mg / kg body weight of the subj ect. In a preferred embodiment, the effective dose is 10-20 mg / kg body weight of the subject. In another related embodiment of the invention, the related complications are selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity', liver steatosis, kidney dysfunction, and glaucoma. In a related aspect the subject is a mammal. In related embodiment of the invention, the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
[0033] The preferred embodiments are further described in detail by means of the following examples. The examples are provided solely for illustration and are not to be construed as limitations of the present disclosure, as many variations thereof are possible without departing from the spirit and scope of the present disclosure.
[0034] Example 1 : Materials
[0035] From the compounds of Formula I Gingerenone A (STR#2) and Hirsutenone (STR#3) are evaluated for their ability to modify the expression of aqaaporins in a diabetic animal model Different methods and processes are available in the literature for the chemical synthesis of Gingerenone A (STR#2 ) and Hirsutenone ( STR#3). These compounds can also be isolated from a plant source, preferably, but not limited to. Zingiber officinale, Alnus hirsuta. Alnus sibirica, Alnus glutinosa, Alnus formosana. Alnus japonica, Alnus nepalensis, Viscum cruciatum using conventionally known extraction processes.
[0036] Example 2: Effect of Gingerenone A and Hirsutenone on pancreatic P-cell function
[0037] Experimental design
[0038] After 1 week of adaptive feeding, the rats were randomly divided into normal control and experimental groups. The experimental group received high-fat diet (consisting of 70 % standard laboratory chow, 15 % carbohydrates, 10 % lard, and 5 % yolk powder) to establish an insulin resistance model, while the normal control group received standard chow. After 4 weeks of high-fat diet feeding, the experimental group rats were induced with diabetes by a single intraperitoneal injection of STZ (35 mg'kg, dissolved in 0.01 M sodium citrate buffer, pH 4.4), while the Normal group rats were injected with the same dose of citrate buffer. At the 7th day after STZ injection, the random blood glucose levels of rats were measured to confirm the successful establishment of the diabetes model. Rats with random blood glucose level > 150 mg / dl were indicative of the establishment of the diabetes and were selected for further pharmacological studies. All rats were fed their respective diets until the end of the study. All drags were administered orally once daily between 9:00 and 11 :00 a.m., continuously for 12 weeks. Table 1 discloses the groups of rats used for the experimentation.
[0039] Table 1: Experimental groups
[0040] Blood and tissue processing
[0041] Blood samples were acquired by cardiac puncture at the time of sacrifice. After anesthetization by chloral hydrate, blood samples were collected via the abdominal aorta and centrifuged at 4000 x g for 10 min at 4 °C to separate the serum for subsequent experiments. Thereafter, the pancreas were immediately harvested and weighed and tissue supernatant was collected for analysis.
[0042] Blood glucose. Serum creatinine, serum albumin, Triglyceride, Total cholesterol. Free Fatty Acid, Phospholipids were estimated using commercially available kits. The expression of aquaporins (AQP7 and AQP12) (Biogenuix Medsystems Pvt. Ltd ). NLRP3 Inflammasomes (Aviva System Biology) and cystatin C (Thermo Scientific) levels were estimated using commercially available ELISA kits
[0043] Effective dose identification
[0044] The blood glucose levels for group of rats in table 1 was estimated and the results are tabulated in table 2:
[0045] Table 2: Glucose levels
[0046] Gingerenone at 10 mg / kg and Hirsutenone at 20 mg / kg showed significant reduction and thus was used further for estimation of other parameters.
[0047] Evaluating levels of Aquaporins and inflammasomes in pancreatic cells
[0048] Aquaporin 7 (AQP7) and aquaporin 12 (AQP12) are implicated in diabetes and beta cell function. AQP7 is the most representative glycerol channel expressed in pancreatic (3-cells, the endocrine cells responsible for insulin production, regulating the blood glucose uptake. Glycerol uptake is followed by a fast [3-cell reswelling, volume- regulated anion channels activation and insulin release. Glycerol kinase phosphorylates glycerol to glycerol-3-phosphate, which is used as a substrate in the glycerol-3- phosphate shuttle, the process that reduces equivalents into mitochondria to be used inoxidative phosphorylation and ATP production. Increasing expression of AQP7 ensures adequate proliferation, migration and adhesion of [3-cells. AQP12 is expressed in pancreatic acinar cells and is localized on tire membrane of intracellular organelles. The intracellular localization of AQP 12 in pancreatic acinar cells suggests a potential role in the maturation and exocytosis of zymogen granule and it has been proposed as a marker of pancreatic damage. AQP12-null mice show increased susceptibility to acute pancreatitis, probably due to a defect in the secretion of zymogens . Moreover, AQP 12 is upregulated in pancreatic steatosis and related to markers of insulin resistance. AQP12 increases cellular adhesion, increases insulin secretion and decreases pro-inflammatory cytokines (da Silva et al., Aquaporin-7 and aquaporin-12 modulate the inflammatory’ phenotype of endocrine pancreatic beta-cells, Archives of Biochemistry and Biophysics, Volume 691, 30 September 2020, 108481).
[0049] In the current study, the levels of AQP7 and AQP 12 were decreased in diabetic rats induced with high fat diet and STZ (Fig. 1 and Fig. 2). Both Gingerenone at 10 mg / kg and Hirsutenone at 20 mg / kg improved the expression of AQP7 and AQP 12 thereby increasing the water homeostasis within the pancreatic cells, increasing insulin secretion and reducing inflammation. There was also a reduction in NLRP-3 expression in the cells indicating reducing in inflammation within the cells (Fig. 3). The Nod-like receptor protein 3 (NLRP3) inflammasome and interleukin (IL- ip)activation in macrophages and dendritic cells leads to release of IL-1 p, which can signal through its receptor on [3 cells to lead to cell death, inhibiting insulin secretory capacity. The increase of these inflammasomes can trigger metabolic changes in diabetes including insulin resistance, hyperlipidaemia and hyperglycaemia and there is subsequent development of diabetic complications including diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy. As almost every' major complication of diabetes, affecting various organ systems including cardiovascular, neurological, renal, and hepatic, is associated with the upregulation of NLRP3 (Nitulescu et al., From Innate Immunity’ to Metabolic Disorder: A Review of the NLRP3 Inflammasome in Diabetes Mellitus, J. Clin. Med. 2023, 12(18), 6022; https: / / doi.org / 10.3390 / jcml2186022), the reduction of NLRP- 3 expression by both Gingerenone and Hirsutenone indicates that these compounds can also prevent diabetes related complications.
[0050] Effect of Gingerenone A and Hirsutenone on the levels of other biomarkers
[0051] Serum cystatin C has been well established as an early and accurate biomarker of CKD {Benoit et al., Cystatin C as a biomarker of chronic kidney disease: latest developments, Expert Rev Mol Diagn. 2020 Oct; 20(10): 1019- -1026). Diabetes has a toll of the kidney function and there is a choric decrease in kidney function with time. The concentration of serum Cystatin C is mainly determined by glomerular filtration, which makes Cystatin C an endogenous marker of glomerular filtration rate. A possible advantage of cystatin C with minor glomerular damage is that, being a large molecule, blood levels of cystatin C rises sooner than creatinine and is an effective biomarker. In the present study, the cystatin C were elevated in high fat diet and STZ rats which was reduced by administration of Gingerenone A (STR#2) and Hirsutenone (STR#3 ) (Fig. 4), indicating the nephroprotective effects of the compounds. The compounds prevent diabetic related complications such as nephropathy, kidney dysfunction etc. The compounds also reduced the levels of creatinine and albumin (Table 3) thereby showing its effect as a complete nephr oprotective agents.
[0052] Table 3: Levels of Creatinine and Albumin
[0053] There was also an associated increase in the levels of triglycerides, total cholesterol and fatty acids and phospholipids in diabetic groups which was reduced by the administration of Gingerenone A (STR#2) and Hirsutenone (STR#3) (Table 4) indicating that the compounds are useful in preventing associated conditions like hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction.
[0054] Table 4: Effect on Biochemical parameters
[0055] Overall, Gingerenone A (STR#2) and Hirsutenone (STR#3 (increased the expression of AQP7 and AQPI2, associated with P-cell proliferation, adhesion and migration which are reduced in diseased state. The AQP12 expression was also increased which makes the cells resistant to inflammation, revealing lower levels of proinflammatory markers. Gingerenone A & Himstenone reduced the expression of NLRP3 Inflammasomes in turn reduce Diabetic Complications arising due to inflammation. Both compounds were shown to inhibit diabetes induced increased levels of blood creatinine, albumin and glucose levels and also reduced the high fat diet induced altered levels of triglycerides, cholesterol, free fatty acids and phospholipids and also improved renal insufficiency by decreasing Cystatin C levels. Gingerenone A & Hirustenone can be used effectively for the management of diabetes and related complications.
[0056] Example 3: Formulations
[0057] Tables 5-18 provide illustrative examples of nutraceutical formulationsTable 5: TabletTable 6; TabletTable 7; TabletTable 8: CapsuleTable 9: CapsuleTable 10: CapsuleTable 11: PowderTable 12: PowderTable 13: Gummy FormulationTable 14: Gummy FormulationTable 15: Gummv FormulationTable 16: Candy FormulationTable 17: Candy FormulationTable 18: Candv Formulation
[0058] Other modifications and variations of the invention will be apparent to those skilled in the art from the foregoing disclosure and teachings. Thus, while only certain embodiments of the invention have been specifically described herein, it will be apparent that numerous modifications may be made thereto without departing from the spirit and scope of the invention.
Claims
We claim,1. A composition comprising compounds of Formula I for use in modulating the expression of aquaporins in a subject with a disease condition.Formula I2. The composition for use as in claim 1 , wherein the compound is selected from the group consisting of Gingerenone A (STR#2) and Hirsutenone (STR&3).
3. The composition for use as in claim 1, the aquaporins are selected from the group consisting of AQPO, AQP1 , AQP2, AQP3. AQP4, AQP5, AQP6. AQP8, AQP7, AQP9, AQP10, AQP1 1, AQP12, and combinations thereof.
4. The composition for use as in claim I, wherein modulating the expression of aquaporins improves water homeostasis in the subject.
5. The composition for use as in claim 1 . wherein the diseases conditions are selected from the group consisting of neurodegenerative diseases, metabolic syndrome, cardiovascular diseases, cancer, inflammatory diseases, allergy, diabetes, insulin resistance, renal disorders, skin hydration, brain edema, immune system disorders, obesity, and liver steatosis.
6. The composition for use as in claim L wherein the subject is a mammal.
7. The composition for use as in claim I , wherein the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
8. A composition comprising compounds of Formula I for use in increasing pancreaticcell function in a subject with a disease condition, wherein increase in P-cell function by the composition is brought about by improving water homeostasis.Formula I9. The composition for use as in claim 8, wherein the compound is selected from the group consisting of Gingerenone A, and Hi rsutenone.
10. The composition for use as in claim 8, wherem the improvement in water homeostasis is brought about by modulating the expression of aquaporins (AQP).1 1. The composition for use as in claim 8. wherein the aquaporins are selected from the group consisting of AQP7 and AQP 12.
12. The composition for use as in claim 8, wherein altering the pancreatic p-cell function results in modulating tire proliferation, adhesion and migration of pancreatic p-cells, decreases the levels of inflammatory cytokines and regularizes insulin secretion.
13. The composition for use as in claim 8, wherein the disease condition is selected from the group consisting of, insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma.
14. The composition for use as in claim 8, wherem the subject is a mammal.
15. The composition for use as in claim 8, wherein the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
16. A composition comprising compounds of Formula I for use in the therapeutic management of diabetes and related complications in a subject.Formula I17. The composition for use as in claim 16, wherein the compound is selected from the group consisting of Gingerenone A and Hirsutenone.
18. The composition for use as in claim 16, wherein management of diabetes is brought about by increasing the pancreatic p-cell function, decreasing circulating levels ofcreatinine, and albumin, decreasing hyperlipidemia, decreasing blood cystatin C levels, and reducing expression of NLRP-3 inflammasomes.
19. The composition for use as in claim 16, wherein the alteration of 3-cell function is brought about by modulating the expression of aquaporins (AQP).
20. The composition for use as in claim 16, wherein the aquaporins is selected from the group consisting of AQP7 and AQP12.
21. The composition for use as in claim 16, wherein hyperlipidemia is reduced by decreasing the levels of triglycerides, total cholesterol, free fatty acids and phospholipids.
22. The composition for use as in claim 16, wherein the related complications is selected from the group consisting of insulin resistance, diabetes, pancreatitis, pancreatic steatosis, diabetic nephropathy, atherosclerosis, diabetic cardiomyopathy, diabetic neuropathy and diabetic retinopathy, hyperglycemia, dyslipidemia, hypercholesterolemia, obesity, liver steatosis, kidney dysfunction, and glaucoma.
23. The composition for use as in claim 16, wherein the subject is a mammal.
24. The composition for use as in claim 16. wherein the composition is formulated with pharmaceutically / nutraceutically acceptable excipients, adjuvants, diluents or carriers, and administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, and eatables.
Citation Information
Patent Citations
Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient
US20100190862A1
Novel diaryl hepatonoid-based compounds and use thereof
US20110124740A1
Food composition for preventing obesity, pharmaceutical composition for treating obesity, and animal medicine for treating obesity, containing gingernone a
US20160074338A1
Cited By
Application of AQP1 in preparation of medicine for treating hyperinsulinemia myocardial injury
CN120754256A
